1
NAMS Certification Exam 2025 EXAM
Questions & Answers | 100% Verified
solutions |Questions with Correct
Answers 2025 latest update!!
Physiology of VMS - (ANSWER)-thermoregulatory center altered by increase in
KNDy neurons
-activation of NK3R causes hot flashes
-blockade of NK3R reduces/eliminates hot flashes
-may also be affected by: serotonin, epinephrine, and norepinephrine;
parasympathetic nerve activity
Off label rx for VMS - (ANSWER)-SSRIs
-SNRIs
-Gabapentinoids
-Clonidine
-Oxybutynin
Studies on Fractional Co2 Laser for GSM - (ANSWER)-not FDA approved
-vaginal symptoms and sexual function scores increased significantly at 3 mon;
noted continued improvement at 1y
Ospemifene (Osphena) indications and MOA - (ANSWER)-for treatment of
dyspareunia
, 2
-decreases vaginal pH
-improves vaginal dryness
-shifts vaginal maturational index to superficial cells
-estrogen agonist/antagonist
Ospemifene (Osphena) adverse effects - (ANSWER)-increase in uterine polyps
-proliferative endometrium
-slight increased risk of hemorrhagic stroke and VTE
-can increase VMS
treatment of urge incontinence - (ANSWER)-behavioral modifications
-overactivity of the detrusor muscle
-antimuscarinics: *oxybutynin*
-nerve stimulation
-botox
pelvic floor muscles - superficial - (ANSWER)-transverse perineal
-bulbospongiosus,
-ischiocavernosus
pelvic floor muscles - deep - (ANSWER)-pubococcygeus
-iliococcygeus
NAMS Certification Exam 2025 EXAM
Questions & Answers | 100% Verified
solutions |Questions with Correct
Answers 2025 latest update!!
Physiology of VMS - (ANSWER)-thermoregulatory center altered by increase in
KNDy neurons
-activation of NK3R causes hot flashes
-blockade of NK3R reduces/eliminates hot flashes
-may also be affected by: serotonin, epinephrine, and norepinephrine;
parasympathetic nerve activity
Off label rx for VMS - (ANSWER)-SSRIs
-SNRIs
-Gabapentinoids
-Clonidine
-Oxybutynin
Studies on Fractional Co2 Laser for GSM - (ANSWER)-not FDA approved
-vaginal symptoms and sexual function scores increased significantly at 3 mon;
noted continued improvement at 1y
Ospemifene (Osphena) indications and MOA - (ANSWER)-for treatment of
dyspareunia
, 2
-decreases vaginal pH
-improves vaginal dryness
-shifts vaginal maturational index to superficial cells
-estrogen agonist/antagonist
Ospemifene (Osphena) adverse effects - (ANSWER)-increase in uterine polyps
-proliferative endometrium
-slight increased risk of hemorrhagic stroke and VTE
-can increase VMS
treatment of urge incontinence - (ANSWER)-behavioral modifications
-overactivity of the detrusor muscle
-antimuscarinics: *oxybutynin*
-nerve stimulation
-botox
pelvic floor muscles - superficial - (ANSWER)-transverse perineal
-bulbospongiosus,
-ischiocavernosus
pelvic floor muscles - deep - (ANSWER)-pubococcygeus
-iliococcygeus